Valuation : Vivesto AB

Market Cap 99.53M 10.27M 8.85M 8.38M 7.6M 14.25M 981M 14.32M 38.27M 499M 38.58M 37.73M 1.58B P/E 2026 *
-2.99x
P/E 2027 * -2.48x
Enterprise Value 91.53M 9.45M 8.14M 7.71M 6.99M 13.1M 902M 13.17M 35.2M 459M 35.48M 34.7M 1.45B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
52.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Vivesto AB

1 day+0.11%
1 week+1.93%
Current month+1.70%
1 month+2.39%
3 months+1.70%
6 months+12.38%
Current year-33.41%
1 week 8.79
Extreme 8.79
9.04
1 month 8.5
Extreme 8.5
9.14
Current year 7
Extreme 7
19.5
1 year 7
Extreme 7
27.3
3 years 7
Extreme 7
90.6
5 years 7
Extreme 7
302.9
10 years 7
Extreme 7
1,670
Manager TitleAgeSince
Chief Executive Officer 68 23/01/2023
Director of Finance/CFO 55 01/07/2026
Chief Tech/Sci/R&D Officer 39 01/01/2023
Director TitleAgeSince
Chairman 46 25/05/2022
Director/Board Member 61 26/09/2019
Director/Board Member 43 25/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
25/3/22 Buy

Chief Executive Officer

12,200 0.0027%
24/3/22 Others

Chairman

120,000 0.0268%
20/12/21 Free

Chief Executive Officer

2,250,000 0.5018%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+1.93%-60.83%-57.09% 10.27M
-0.65%-2.93%+47.52%+87.34% 994B
-0.29%-3.51%+48.78%+63.27% 640B
+0.83%+0.26%+16.76%+72.52% 454B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
Average -0.65%-4.99%+12.38%+31.11% 350.48B
Weighted average by Cap. -0.51%-4.42%+29.87%+55.71%

Financials

2026 *2027 *
Net sales - -
Net income -31M -3.2M -2.76M -2.61M -2.37M -4.44M -306M -4.46M -11.92M -156M -12.02M -11.75M -491M -40M -4.13M -3.56M -3.37M -3.05M -5.73M -394M -5.76M -15.38M -201M -15.5M -15.16M -634M
Net Debt -8M -826K -711K -674K -611K -1.15M -78.88M -1.15M -3.08M -40.13M -3.1M -3.03M -127M -17M -1.75M -1.51M -1.43M -1.3M -2.43M -168M -2.45M -6.54M -85.28M -6.59M -6.44M -269M
Logo Vivesto AB
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Employees
4
Date Price Change Volume
11/09/26 SEK 8.990 +0.11% 918
10/09/26 SEK 8.980 -0.22% 6,457
09/09/26 SEK 9.000 +2.27% 6,779
08/09/26 SEK 8.800 -2.00% 3,017
07/09/26 SEK 8.980 +1.81% 2,950

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIVE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!